Both these mechanisms may confer the suppression of BCR-ABL expression and result in reduced proliferation and increased apoptosis in CML cells regardless of T315I -BCR-ABL mutation status. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.